MFG
ADVM

Merit Financial Group’s Adverum Biotechnologies ADVM Stock Holding History

Merit Financial Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$5.79K – 635
2022
Q4 		$5.79K Hold
1,000
– – ﹤0.01% 692
2022
Q3 		$10K Hold
1,000
– – ﹤0.01% 568
2022
Q2 		$12K Buy
+1,000
New +$10.5K ﹤0.01% 570

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Merit Financial Group's ADVM Position: Q1 2023 in Review

Merit Financial Group sold out of Adverum Biotechnologies (ADVM) in Q1 2023, closing a stake of 1,000 shares — an estimated $5.79K sold.

Merit Financial Group first reported a position in ADVM in Q2 2022 and held it in 3 quarters. The position peaked at $12K in Q2 2022. 55 funds tracked by Wall St. Rank hold ADVM as of Q1 2023.

  • Merit Financial Group reported no remaining Adverum Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Merit Financial Group sold 1,000 Adverum Biotechnologies shares in Q1 2023, an estimated $5.79K.
  • Merit Financial Group first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 3 quarters.
  • Merit Financial Group's Adverum Biotechnologies position peaked at $12K in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.